Milan, 9th May 2016
Rheumatoid Arthritis and other rheumatic diseases are chronic pathologies characterized by high direct and indirect social costs. Thanks to the pharmacological innovation, these diseases can be attacked and managed, provided that they are faced promptly, in order to maximize the suitability of the provision of treatments.
The wide experience in use suggests some differences between treatments defined by clinical trials and those current in the real world. These differences have effects on the management of the pathology, health condition and quality of life of patients, but also on the cost of the therapy. Starting from these premises, through the data analysis the conference wants to highlight the various Regional experiences for treatments with biological drugs for rheumatic pathologies.